T-DM1 extended progression-free survival by 40% in HER2+ metastatic breast cancer and was less toxic, compared with standard therapy.
By Bonnie Gillis
Advertisement
Articles by By Bonnie Gillis
Investigational drug that emits alpha radiation shows significant improvement in overall survival.
Two studies enhance understanding of risk factors for prostate cancer.
Being obese at the time operable breast cancer is diagnosed is associated with inferior outcomes in women with estrogen receptor (ER) or progesterone receptor (PR)positive, HER2-negative breast cancer.
Advertisement
Latest Updated Articles
Two Predictors of Prostate Cancer Explored in Healthy MenPublished: September 23rd 2011 | Updated:
- Survival Benefit Shown With Investigational Alpha-Emitting Radiopharmaceutical in Men With Hormone Resistant Metastatic Prostate Cancer
Published: September 24th 2011 | Updated:
- T-DM1 Achieves Longer Progression-Free Survival vs. Standard Therapy in HER2+ Metastatic Breast Cancer
Published: September 25th 2011 | Updated:
- SABCS 2010: Obesity Ups Risk of Recurrence for Some Women With HER2-Negative Breast Cancer
Published: March 4th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5